Odense University Hospital
- Address
- Indgang 87-88, Kloevervaenget 2, 5000 Odense, Denmark
Neoplasms – Endometrial Cancer
At Odense University Hospital, investigators are evaluating a novel immunotherapy combined with standard post‑surgical treatment for women with high‑risk disease. The purpose is to improve long‑term outcomes by reducing cancer recurrence.
- Disease‑free survival assessment
- Overall survival measurement
- Combination with adjuvant chemotherapy
- Optional radiotherapy integration
- Post‑surgical curative intent
The study seeks to determine whether adding the immune‑checkpoint inhibitor can extend both disease‑free and overall survival, offering a potential new standard of care for patients.
Respiratory Tract Diseases – Idiopathic Pulmonary Fibrosis
In a collaborative effort at Odense University Hospital, researchers are testing an inhaled therapy designed to target fibrotic pathways in the lungs. The trial focuses on safety and early signals of efficacy in a progressive lung condition.
- Inhaled MMP7 inhibitor evaluation
- Safety and tolerability monitoring
- Pulmonary function testing
- Biomarker profiling
- Quality‑of‑life assessment
By exploring a localized treatment approach, the research hopes to slow disease progression and improve breathing capacity for patients with this challenging condition.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Celgene Corp.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Odense University Hospital
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) | Celgene Corp. | Phase IV | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| ADMILPARANT | 1 | Unknown | 2024-07-15 | 2024-07-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.